Art. -Nr.: HY-15417

ML-7 hydrochloride

24 Cited Publications

Kundenbewertung

Based on 24 publication(s) in Google Scholar

ML-7 hydrochloride is a selective and highly specific myosin light chain kinase (MLCK) inhibitor that acts as a trabecular meshwork (TM) relaxant. ML-7 hydrochloride enhances Quinocetone (HY-123581)-induced phosphorylation of ERK, p38 MAPK and JNK, attenuates Akt activation, and promotes apoptosis of hepatocellular carcinoma cells. ML-7 hydrochloride reduces Th2 cytokine secretion by inhibiting MLCK, while alleviating smooth muscle hyperplasia and collagen deposition. As a non-antibiotic adjuvant, ML-7 hydrochloride restores the sensitivity of drug-resistant bacteria to Tigecycline (HY-B0117). ML-7 hydrochloride can be used in research related to glaucoma, hepatocellular carcinoma, asthma, and Klebsiella pneumoniae infection.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.60%
CAS. Nr.: 110448-33-4
Formel: C₁₅H₁₈ClIN₂O₂S
Molecular Weight:452.74

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

ML-7 hydrochloride Chemical Structure

CAS. Nr.: 110448-33-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (24)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

YAP/TAZ

Alle Myosin Isoform-spezifische Produkte anzeigen :

MLCK

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle JNK Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

In Vitro

ML-7 (10-20 μM; 24 h) hydrochloride alone shows no toxicity to HepG2 cells, but enhances quinocetone-induced cytotoxicity in a dose-dependent manner, and significantly reduces cell viability when used in combination with quinocetone^[1].
ML-7 (15-20 μM; 24 h) hydrochloride alone does not induce significant apoptosis in HepG2 cells, but when combined with quinocetone, it significantly enhances quinocetone-induced apoptosis in a dose-dependent manner^[1].
ML-7 (20 μM; 24 h) hydrochloride enhances quinocetone-induced activation of both extrinsic and intrinsic apoptotic pathways in HepG2 cells by promoting the cleavage of key caspases, PARP-1 and Bid, as well as upregulating the pro-apoptotic Bax/Bcl-2 ratio^[1].
ML-7 (20 μM; 24 h) hydrochloride significantly amplifies quinocetone-induced loss of mitochondrial membrane potential in HepG2 cells, thereby promoting an increase in endogenous apoptosis levels^[1].
ML-7 (20 μM; 24 h) hydrochloride attenuates quinocetone-induced activation of the pro-survival Akt pathway and enhances quinocetone-induced activation of the JNK, p38 and ERK MAPK pathways in HepG2 cells^[1].
ML-7 (20 μM; 15 min) hydrochloride inhibits the increase in MLCK activity in phagocytosing human neutrophils^[2].
ML-7 (20 μM) hydrochloride inhibits the upregulation of cell surface ALPase activity (a marker of reactive oxygen species-producing granule exocytosis) in PMA-stimulated human neutrophils, with an inhibition rate of 86% when treated before stimulation and 75% when treated after stimulation^[2].
ML-7 (20 μM) hydrochloride inhibits extracellular O₂⁻ release from human neutrophils stimulated by phorbol ester (PMA) (HY-18739); administration prior to stimulation results in complete inhibition, while administration after stimulation achieves approximately 80% inhibition^[2].
ML-7 (20 μM) hydrochloride does not inhibit PMA-stimulated O₂⁻ production in human neutrophils, but prolongs the lag phase of oxidant production when administered prior to stimulation^[2].
ML-7 (20 μM; 5 min) hydrochloride fails to prevent the formation of intracellular O₂⁻-producing compartments in PMA-stimulated human neutrophils, regardless of whether it is administered before or after stimulation^[2].
ML-7 (20 μM) hydrochloride does not inhibit NADPH oxidase activity in phorbol ester (PMA)-stimulated human neutrophils, but reduces the association of oxidant-producing compartments with the plasma membrane^[2].
ML-7 (20 μM; 5 min) hydrochloride inhibits the association of pro-oxidant intracellular compartments with the plasma membrane in PMA-stimulated human neutrophils, with a suppression rate of 87% for pre-stimulation treatment and 81% for post-stimulation treatment^[2].
ML-7 (1-5 μM) hydrochloride dose-dependently inhibits carbachol (HY-B1208)-induced contractility of isolated bovine trabecular meshwork strips, with an inhibition rate of 25.1% at the concentration of 5 μM^[3].
ML-7 (1 μM) hydrochloride reduces endothelin-1-induced contractile force in isolated bovine trabecular meshwork strips to 35.9% of the maximal contractile force induced by carbachol^[3].
ML-7 (1 μM) hydrochloride reduces the serine phosphorylation level of myosin light chain kinase in carbachol-induced native bovine trabecular meshwork muscle strips^[3].
ML-7 (4-128 μg/mL; 18 h) hydrochloride acts as a potent adjuvant that synergizes with tigecycline against all tested clinical tigecycline-resistant Klebsiella pneumoniae isolates (7 sequence types), with fractional inhibitory concentration index (FICI) values ≤ 0.5, and reduces the MIC of tigecycline by 4- to 128-fold^[4].
Combination treatment with ML-7 (64 μg/mL; 24 h) hydrochloride and tigecycline at 2 μg/mL completely inhibits the growth of tigecycline-resistant Klebsiella pneumoniae isolates 14-R71, 14-R74 and 14-R75 within 24 h, whereas monotherapy with either drug only achieves partial growth inhibition^[4].
The combination of ML-7 (64 μg/mL; 24 h) hydrochloride and 2 μg/mL tigecycline exerts synergistic bactericidal activity against tigecycline-resistant Klebsiella pneumoniae isolates 14-R71 and 14-R75 (reducing CFU/mL by approximately 5-6 log₁₀), and exhibits synergistic bacteriostatic activity against isolate 14-R74 within 24 h, whereas no significant effect is observed with either drug used alone^[4].
ML-7 (32-128 μg/mL; 1 h) hydrochloride inhibits the activity of efflux pumps in tigecycline-resistant Klebsiella pneumoniae in a dose-dependent manner, and its combined use enhances the inhibitory effect of tigecycline on such efflux pumps^[4].
ML-7 (32-128 μg/mL; 30 min) hydrochloride disrupts the proton motive force of tigecycline-resistant Klebsiella pneumoniae 14-R75 by significantly increasing ΔpH, and this effect occurs when ML-7 is used alone or in combination with tigecycline^[4].
ML-7 (32-128 μg/mL) hydrochloride reduces the outer membrane permeability of tigecycline-resistant Klebsiella pneumoniae in a dose-dependent manner, either when used alone or in combination with tigecycline, but has no effect on inner membrane permeability^[4].
ML-7 (4 h) hydrochloride alters the transcriptome of tigecycline-resistant Klebsiella pneumoniae 14-R75, and genes associated with its mechanism of action are mainly enriched in ABC transporters, including downregulated expression of the efflux pump component macB^[4].
ML-7 (32-128 μg/mL; 30 min) hydrochloride induces dose-dependent accumulation of reactive oxygen species in tigecycline-resistant Klebsiella pneumoniae 14-R75, either when acting alone or in combination with tigecycline^[4].
ML-7 (32-128 μg/mL) hydrochloride dose-dependently reduces the intracellular ATP level of tigecycline-resistant Klebsiella pneumoniae 14-R75, and this effect occurs both when ML-7 acts alone and when it is used in combination with tigecycline^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HepG2 human hepatocellular carcinoma cells
Concentration:

10, 15 and 20 μM (in combination with Quinocetone)
Incubation Time:

24 h
Result:

Did not cause significant changes in HepG2 cell viability compared to controls when used alone.
Reduced cell viability from 80.70% to 64.62% when co-treated with 5 μg/mL quinocetone at 15 μM.
Reduced cell viability to 53.20% when co-treated with 5 μg/mL quinocetone at 20 μM.
Produced similar dose-dependent reductions in cell viability relative to quinocetone alone when co-treated with 7.5 or 10 μg/mL quinocetone plus 15 or 20 μM.

Apoptosis Analysis^[1]

Cell Line:

HepG2 human hepatocellular carcinoma cells
Concentration:

15 and 20 μM (in combination with Quinocetone)
Incubation Time:

24 h
Result:

Did not cause significant changes in apoptotic cell percentages compared to controls when used alone.
Raised the apoptotic cell ratio from 5.13% to 10.95% when co-treated with 5 μg/mL quinocetone at 20 μM.
Raised the apoptotic cell ratio from 10.65% to 20.53% when co-treated with 7.5 μg/mL quinocetone at 20 μM.
Increased apoptotic cell rates to 15.51% and 34.69% when co-treated with 5 μg/mL and 7.5 μg/mL quinocetone respectively at 20 μM.

Western Blot Analysis^[1]

Cell Line:

HepG2 human hepatocellular carcinoma cells
Concentration:

20 μM (in combination with Quinocetone)
Incubation Time:

24 h
Result:

Enhanced quinocetone-induced cleavage of caspase-3, PARP-1, caspase-8, caspase-9, and Bid when co-treated with quinocetone.
Amplified quinocetone-induced upregulation of the Bax/Bcl-2 ratio compared to quinocetone alone.
Did not produce significant changes in these proteins relative to controls when used alone.

Western Blot Analysis^[1]

Cell Line:

HepG2 human hepatocellular carcinoma cells
Concentration:

20 μM (in combination with 5-10 μg/mL quinocetone)
Incubation Time:

24 h
Result:

Attenuated quinocetone-induced activation of the Akt pathway, without changing total Akt or S6K levels, when co-treated with quinocetone.
Amplified quinocetone-induced phosphorylation of JNK, p38, and ERK, and increased total JNK and ERK levels compared to quinocetone alone, when co-treated with quinocetone.

Western Blot Analysis^[1]

Cell Line:

HepG2 human hepatocellular carcinoma cells
Concentration:

20 μM (in combination with 7.5 μg/mL Quinocetone, preceded by 30 min pretreatment with 10 μM SB203580, 10 μM U0126, 10 μM SP600125, or 50 ng/mL IGF-1)
Incubation Time:

24 h (combo treatment; preceded by 30 min pretreatment)
Result:

Reduced combo-induced cleavage of PARP-1, caspase-3, caspase-9, caspase-8, and Bid, and reduced the combo-induced Bax/Bcl-2 ratio when cells were pretreated with SB203580 or IGF-1.
Enhanced combo-induced cleavage of these proteins and increased the Bax/Bcl-2 ratio when cells were pretreated with U0126 or SP600125.

Chemical Information

CAS. Nr. 110448-33-4
Appearance Solid
Molecular Weight 452.74
Formel C₁₅H₁₈ClIN₂O₂S
Color Off-white to yellow
SMILES

O=S(N1CCNCCC1)(C2=C3C=CC=C(I)C3=CC=C2)=O.Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Publications (24)

All WB

Sort by:

Journal Impact Factor

Immunity

Neutrophil "plucking" on megakaryocytes drives platelet production and boosts cardiovascular disease. [Abstract]

2022 Dec 13;55(12):2285-2299.e7. PMID: 36272416
Bioact Mater

Creating a bionic scaffold via light-curing liquid crystal ink to reveal the role of osteoid-like microenvironment in osteogenesis. [Abstract]

2024 Jun 14:40:244-260. PMID: 38973990
Carbohydr Polym

Highly anisotropic and elastic cellulosic scaffold guiding cell orientation and osteogenic differentiation via topological and mechanical cues. [Abstract]

2023 Dec 1:321:121292. PMID: 37739527
Food Res Int

2026 Feb 11.
Cell Mol Gastroenterol Hepatol

Fibrinogen/AKT/Microfilament Axis Promotes Colitis by Enhancing Vascular Permeability. [Abstract]

2021;11(3):683-696. PMID: 33075564
J Invest Dermatol

Hair follicle transit amplifying cells phagocytose dead cells after radiotherapeutic and chemotherapeutic injuries for timely regeneration. [Abstract]

2024 Feb;144(2):243-251.e2. PMID: 37598868
J Agric Food Chem

Mechanism of Intestinal Epithelial Absorption and Electrophysiological Regulation of the Shrimp Peptide QMDDQ. [Abstract]

2024 Jan 10;72(1):326-338. PMID: 38155399
J Agric Food Chem

Aflatoxin B1 Induces Intestinal Barrier Dysfunction by Regulating the FXR-Mediated MLCK Signaling Pathway in Mice and in IPEC-J2 Cells. [Abstract]

2023 Jan 11;71(1):867-876. PMID: 36579420
J Agric Food Chem

Reparative Effects of Ethanol-Induced Intestinal Barrier Injury by Flavonoid Luteolin via MAPK/NF-κB/MLCK and Nrf2 Signaling Pathways. [Abstract]

2021 Apr 14;69(14):4101-4110. PMID: 33749262

ML-7 hydrochloride purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2021 Apr 14;69(14):4101-4110. [Abstract]

Relative protein expression of ZO-1 pretreated with 10 μmol/L ML7 for 1 h. ML7 directly inhibits the expression of ZO-1.
Ecotoxicol Environ Saf

Imidacloprid increases intestinal permeability by disrupting tight junctions. [Abstract]

2021 Oct 1:222:112476. PMID: 34214772
J Mol Cell Biol

The mechanoresponsive chromosomal passenger complex sustains furrow ingression under confinement. [Abstract]

2025 Jul 22:mjaf019. PMID: 40693957
Cells

Single-Cell Hypertrophy Promotes Contractile Function of Cultured Human Airway Smooth Muscle Cells via Piezo1 and YAP Auto-Regulation. [Abstract]

2024 Oct 14;13(20):1697. PMID: 39451215
Int J Mol Sci

iE-DAP Induced Inflammatory Response and Tight Junction Disruption in Bovine Mammary Epithelial Cells via NOD1-Dependent NF-κB and MLCK Signaling Pathway. [Abstract]

2023 Mar 27;24(7):6263. PMID: 37047240

ML-7 hydrochloride purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Mar 27;24(7):6263. [Abstract]

ML-7 hydrochloride (ML-7; 10 μM; 2 h; pretreatment) significantly reduces the protein level of phosphorylated MLC2 and the phosphorylation ratio of MLC2 in BMECs.
PLoS Pathog

Streptococcal autolysin promotes dysfunction of swine tracheal epithelium by interacting with vimentin. [Abstract]

2022 Aug 3;18(8):e1010765. PMID: 35921364
Environ Toxicol Pharmacol

ZC3H4 Governs Epithelial Cell Migration through ROCK/p-PYK2/p-MLC2 Pathway in Silica-induced Pulmonary Fibrosis. [Abstract]

2023 Nov:104:104301. PMID: 37866415
Eur J Cell Biol

The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension. [Abstract]

2024 May 28;103(2):151427. PMID: 38820882
J Sci Food Agric

Mechanism of intestinal paracellular absorption of shrimp peptide QMDDQ regulated by myosin light chain kinase. [Abstract]

2025 Jul 1. PMID: 40590404
J Cell Sci

Nuclear F-actin and Lamin A antagonistically modulate nuclear shape. [Abstract]

2022 Jul 1;135(13):jcs259692. PMID: 35665815
Toxicol Lett

Arsenite-induced downregulation of occludin in mouse lungs and BEAS-2B cells via the ROS/ERK/ELK1/MLCK and ROS/p38 MAPK signaling pathways. [Abstract]

2020 Oct 10;332:146-154. PMID: 32683294

ML-7 hydrochloride purchased from MedChemExpress. Usage Cited in: Toxicol Lett. 2020 Oct 10;332:146-154. [Abstract]

Cells are incubated with 10 μM ML-7 for 1 h, followed by incubation with 1.0 μM As2O3 for 24 h and assessment of occludin protein expression with Western blotting.
Virology

The actin cytoskeleton is important for pseudorabies virus infection. [Abstract]

2024 Dec:600:110233. PMID: 39255726
Biochem Biophys Res Commun

YAP nuclear translocation facilitates radiation resistance in nasopharyngeal carcinoma cells. [Abstract]

2023 Aug 30:670:109-116. PMID: 37290285
bioRxiv

Spatially Distinct Myosin II Architectures Regulate Protrusion Dynamics and Directional Persistence during Immune Cell Migration. [Abstract]

2026 Mar 16:2026.03.13.711384. PMID: 41889862
bioRxiv

2024 Jan 23.
bioRxiv

2023 Feb 5.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 43 mg/mL (94.98 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1.43 mg/mL (3.16 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2088 mL

11.0439 mL

22.0877 mL

5 mM

0.4418 mL

2.2088 mL

4.4175 mL

10 mM

0.2209 mL

1.1044 mL

2.2088 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.67 mg/mL (3.69 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (3.69 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhou Y, et al. ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line. Toxicology mechanisms and methods. 2016;26(1):11-21. [Content Brief]

[2]. Odani K, et al. ML-7 inhibits exocytosis of superoxide-producing intracellular compartments in human neutrophils stimulated with phorbol myristate acetate in a myosin light chain kinase-independent manner. Histochemistry and cell biology. 2003 May;119(5):363-70. [Content Brief]

[3]. Rosenthal R, et al. Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Experimental eye research. 2005 Jun;80(6):837-45. [Content Brief]

[4]. Sun L, et al. A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant Klebsiella pneumoniae. Front Cell Infect Microbiol. 2022 Jan 5;11:809542.
[Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.2088 mL	11.0439 mL	22.0877 mL	55.2193 mL
DMSO	5 mM	0.4418 mL	2.2088 mL	4.4175 mL	11.0439 mL
	10 mM	0.2209 mL	1.1044 mL	2.2088 mL	5.5219 mL
	15 mM	0.1473 mL	0.7363 mL	1.4725 mL	3.6813 mL
	20 mM	0.1104 mL	0.5522 mL	1.1044 mL	2.7610 mL
	25 mM	0.0884 mL	0.4418 mL	0.8835 mL	2.2088 mL
	30 mM	0.0736 mL	0.3681 mL	0.7363 mL	1.8406 mL
	40 mM	0.0552 mL	0.2761 mL	0.5522 mL	1.3805 mL
	50 mM	0.0442 mL	0.2209 mL	0.4418 mL	1.1044 mL
	60 mM	0.0368 mL	0.1841 mL	0.3681 mL	0.9203 mL
	80 mM	0.0276 mL	0.1380 mL	0.2761 mL	0.6902 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

ML-7 hydrochloride

24 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ML-7 hydrochloride

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Immunopotentiator Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) ML-7 hydrochloride

Alle Myosin Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Alle JNK Isoform-spezifische Produkte anzeigen

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (24)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

ML-7 hydrochloride Related Classifications

HY-15417 Related Classifications